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Aging is associated with structural and functional changes in the vasculature, including
endothelial dysfunction, arterial stiffening and remodeling, impaired angiogenesis, and
defective vascular repair, and with increased prevalence of atherosclerosis. Cardiovas-
cular risk is similar for older men and women, but lower in women during their fertile
years.This age- and sex-related difference points to estrogen as a protective factor because
menopause is marked by the loss of endogenous estrogen production. Experimental and
some clinical studies have attributed most of the protective effects of estrogen to its
modulatory action on vascular endothelium. Estrogen promotes endothelial-derived NO
production through increased expression and activity of endothelial nitric oxide synthase,
and modulates prostacyclin and thromboxane A2 release. The thromboxane A2 pathway
is key to regulating vascular tone in females. Despite all the experimental evidence,
some clinical trials have reported no cardiovascular beneﬁt from estrogen replacement
therapy in older postmenopausal women. The “Timing Hypothesis,” which states that
estrogen-mediated vascular beneﬁts occur only before the detrimental effects of aging
are established in the vasculature, offers a possible explanation for these discrepancies.
Nevertheless, a gap remains in current knowledge of cardiovascular aging mechanisms
in women. This review comprises clinical and experimental data on the effects of aging,
estrogens, and hormone replacement therapy on vascular function of females.We aim to
clarify how menopause and aging contribute jointly to vascular aging and how estrogen
modulates vascular response at different ages.
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INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of mortality
in both men and women in developed countries. Nonetheless,
sex-associated differences regarding the age of CVD onset and its
progression are observed worldwide. Incidence of CVD in pre-
menopausal women is markedly lower than age-matched men in
epidemiological studies (Messerli et al., 1987; Bairey Merz et al.,
2006; Shaw et al., 2006). After menopause, however, the incidence
is comparable or even higher in women than in men (Lerner and
Kannel,1986; Eaker et al., 1993),makingCVD theprimary cause of
death in postmenopausal women (55 versus 43% in men), exceed-
ing all cancer deaths (Rosamond et al., 2008). The lower CVD
risk among fertile women is often attributed to the protective role
of estrogens at the vascular level. According to epidemiological
observations and extensive basic research, estrogen and other sex
steroids have direct cardiovascular beneﬁts. Estrogen modulates
a myriad of molecular pathways that improve vascular function,
whether at the physiological level or when administered as hor-
mone replacement therapy (HRT; Grodstein et al., 2000, 2001;
Miller and Duckles, 2008).
Nevertheless, some clinical studies have questioned the pro-
tective value of HRT against vascular disease. Two randomized
clinical trials, the Women’s Health Initiative (WHI; Rossouw et al.,
2002) and the Heart and Estrogen/Progestin Replacement Study
(HERS I and II; Gambacciani et al., 2002), indicate that HRT
may increase CVD risk and events in postmenopausal women.
The reason for this paradox could be attributable to many patient
characteristics, including age.
Although aging occurs progressively in both men and women,
the onset of menopausemarks a sudden increase in the appearance
of aging-associated signs in women, and more speciﬁcally in the
progress of vascular aging. Information about the role of age and
menopause in the development of CVD in women is scarce. This
review of clinical and experimental data on the effects of aging,
estrogens, and HRT on vascular function of females aims to clarify
how menopause and aging contribute jointly to vascular aging and
how estrogen modulates vascular response at different ages.
HOW DO ESTROGENS AFFECT VASCULAR FUNCTION?
The numerous vascular effects of estrogens are triggered by com-
plex genomic and non-genomic mechanisms. They include mod-
ulation of vascular function and inﬂammatory response as well
as metabolic and hemodynamic effects. Estradiol, the most abun-
dant and potent estrogen in humans, mainly binds and activates
estrogen receptors (ERs). Vascular estrogen signaling involves at
least three ERs identiﬁed in both vascular smooth muscle and
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endothelium, reinforcing the idea that estrogen has a key role in
controlling vascular function. The classical subtypes ERα (Soloff
and Szego, 1969) and ERβ (Kuiper et al., 1996) vary not only in
their tissue distributions, but also in their agonist/antagonist pro-
ﬁle with respect to several compounds (Cano and Hermenegildo,
2000). These ER subtypes belong to the intracellular receptors
classically deﬁned as nuclear ligand-activated transcription fac-
tors. Activation of these receptors by the corresponding hormones
affects gene expression by acting on estrogen-response elements
in the target genes and modulating transcriptional events (Beato
et al., 1995). Estrogen binding to ERα and ERβ regulates gene
expression in a time- and tissue-dependent manner, generating
controversy about the type of receptor involved in vascular pro-
tection (Murphy, 2011). In the cardiovascular system, both ERα
and ERβ have been identiﬁed in the endothelium, smooth mus-
cle cells, adventitia, and adrenergic nerve endings of arteries from
various territories and several species, including humans (Karas
et al., 1994; Kim-Schulze et al., 1996; Venkov et al., 1996; Register
and Adams, 1998). Although it has been reported that cultured
endothelial cells do not express ERα (Toth et al., 2009), other
investigators have demonstrated the presence of both ERα and
ERβ mRNA in endothelium (Wagner et al., 2001) and data from
our group demonstrate the protein expression of both ERα and
ERβ in HUVEC (Sobrino et al., 2009, 2010).
In addition to their classic nuclear location, ER can also tar-
get the plasma membrane, enabling estrogen activation of several
signaling pathways, including those involved in calcium mobiliza-
tion (Zhang et al., 1994; Nakajima et al., 1995; Prakash et al., 1999)
and the phosphatidylinositol-3-kinase (PI3K) pathway (Hisamoto
et al., 2001). A third type of ER, G-protein coupled, and mainly
located in the plasma membrane, was initially named GPR30
(Takada et al., 1997), then renamed GPER by the International
Union of Basic and Clinical Pharmacology, IUPHAR (Alexan-
der et al., 2008). GPER is expressed in both endothelial and
smooth muscle cells of human arteries and veins (Haas et al., 2007;
Deschamps and Murphy, 2009). After estrogen binding, GPER
activates rapid signaling cascades such as extracellular signal-
related kinase and PI3K (Meyer et al., 2011). Several rapid and
non-genomic estrogen effects formerly attributed toERαhavenow
been described as GPER-mediated (Prossnitz and Barton, 2011).
The vascular protection conferred by estrogen may be medi-
ated indirectly by its inﬂuence on the metabolism of lipoproteins
or by a direct action on the modulation of molecular path-
ways in the vessel wall, and more speciﬁcally on endothelial cells
(Hermenegildo et al., 2002). Vascular endothelium not only reg-
ulates vascular tone through ﬂow-mediated mechanisms, but also
confers antithrombotic and antiinﬂammatory properties to the
blood vessel. Nitric oxide (NO), the primary endothelial-derived
mediator, is involved in many physiological processes, including
vasodilation and inhibition of thrombosis, cell migration, and
proliferation (Dudzinski and Michel, 2007; Lamas et al., 2007;
Michel and Vanhoutte, 2010). Estrogen is known to increase NO
bioavailability by mechanisms that either directly increase NO
generation (Figure 1) or decrease superoxide anion (O−2 ) con-
centration, thereby attenuating O−2 -mediated NO inactivation.
Mechanisms involved in estrogen-induced increases in NO avail-
ability include: (1) transcriptional stimulation of endothelial NO
synthase (eNOS) gene expression (Huang et al., 1997; Sumi and
Ignarro, 2003); (2) non-genomic activation of enzyme activity via
a PI3K/phosphokinase B (PKB/AKT)-mediated signaling pathway
(Hisamoto et al., 2001); (3) increased intracellular free Ca2+ con-
centration ([Ca2+]i) in endothelial cells (Rubio-Gayosso et al.,
2000); (4) decreased production of asymmetric dimethylarginine
(ADMA), the eNOS endogenous inhibitor (Monsalve et al., 2007);
and (5) attenuated O−2 concentrations (Wassmann et al., 2001;
Dantas et al., 2002; Ospina et al., 2002).
Estrogens such as 17β-estradiol, estrone, and estriol have been
described to act as reactive oxygen species (ROS) scavengers by
virtue of the hydrogen-donating capacity of their phenolic molec-
ular structure (Halliwell and Grootveld, 1987; Dubey and Jackson,
2001). However, in these studies the direct effect of estrogens as
scavengers can only be observed at concentrations above 1μM
(Arnal et al., 1996; Kim et al., 1996). Considering that plasma
concentrations of estrogen in physiological conditions are within
the nanomolar range, it is likely that direct scavenger action is
not estrogen’s main antioxidant mechanism. Estrogen modulates
ROS concentration through a mechanism that involves interac-
tion with its estrogenic nuclear receptors to decrease oxidative
proteins and/or increase antioxidant enzymes expression. Many
studies have associated changes in estrogen levels with altered
levels of antioxidant enzymes including glutathione peroxidase,
catalase, and superoxide dismutase (Capel et al., 1981; Robb and
Stuart, 2011; Sivritas et al., 2011). Moreover, estrogen modulates
NADH/NADPH oxidases and AT1 receptor gene expression, both
of which are major sources of O−2 production (Wassmann et al.,
2001; Dantas et al., 2002).
Estrogen also has a modulating effect on constrictive factors
and positively upregulates the production of endothelium-derived
relaxing factors such as PGI2 (Sobrino et al., 2009, 2010) and
the endothelium-derived hyperpolarizing factors (Golding and
Kepler, 2001), both of which are important mediators of vas-
cular relaxation in resistance-sized arteries. The beneﬁcial effects
of estrogen on the endothelium can be partially explained by an
inhibitory effect on the production or action of the cyclooxygenase
(COX)-derived vasoconstrictor agents prostaglandin H2, PGH2,
and thromboxane A2, TXA2 (Davidge and Zhang, 1998; Dantas
et al., 1999; Novella et al., 2010), and of endothelin-1 (ET-1; David
et al., 2001).
Furthermore, estrogen can interfere with ion channels through
non-genomic actions. It regulates contractile responses by a direct
modulation of Ca2+ mobilization into the vascular smooth mus-
cle cells. Direct interaction of estradiol with voltage-gated Maxi-K
channel subunit beta, which confers higher Ca2+ sensitivity, may
modulate vascular smooth muscle (Valverde et al., 1999). Estro-
gen does not inhibit Ca2+ release from the intracellular stores
(Crews and Khalil, 1999; Murphy and Khalil, 1999). However,
supraphysiological concentrations of estrogen impedeCa2+ inﬂux
from the extracellular space (Han et al., 1995; Crews and Khalil,
1999; Murphy and Khalil, 1999) by inhibiting Ca2+ entry through
voltage-gated Ca2+ channels (Freay et al., 1997; Kitazawa et al.,
1997; Crews and Khalil, 1999; Murphy and Khalil, 1999). Expres-
sion of the L-type Ca2+ channels in cardiac muscle is substantially
increased in ER-deﬁcient mice (Johnson et al., 1997), suggesting
ER-mediated regulation of Ca2+ mobilization.
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FIGURE 1 | Dual effects of estradiol (E2) on eNOS expression and
activity. Estradiol effects on eNOS-mediated nitric oxide (NO) production
include both genomic and non-genomic effects. Genomic effects include
the classical intracellular estrogen receptors (ER), which after binding of E2
interact with estrogen-response element (ERE) in DNA, resulting in an
increased eNOS expression. Moreover, E2 binding to GPER leads to
activation of different transcriptional factors such as cAMP response
element (CRE) which also induces eNOS expression. Among non-genomic
effects, ER and GPER regulate the E2-induced eNOS activity (modiﬁed
from Sobrino, 2011).
Estrogen also exerts direct modulation on the components of
the renin-angiotensin system (RAS), a key regulator of blood pres-
sure and smooth muscle cell growth. Production of angiotensin II
(Ang II), the active hormone of the RAS, is reduced by estrogen
inhibition of angiotensin-converting enzyme (ACE) expression.
In animal models of menopause and in postmenopausal women,
chronic estrogen replacement reduces ACE activity in the circu-
lation and in tissues including the kidney and aorta (Brosnihan
et al., 1999; Seely et al., 2004). Furthermore, estrogen attenuates
expression of and tissue response to type 1 angiotensin receptor
(AT1) in the aorta, heart, and kidney (Silva-Antonialli et al., 2000;
Wu et al., 2003).
THE PROCESS OF VASCULAR AGING: HOW ARE FEMALES
AFFECTED?
Vascular aging is associated with endothelial dysfunction, arte-
rial stiffening and remodeling, impaired angiogenesis, defective
vascular repair, and an increasing prevalence of atherosclerosis
(Lakatta and Levy, 2003; Erusalimsky, 2009). Aging-associated
changes in structure and function of large elastic arteries are
seen even in the absence of clinical CVD (Moreau et al., 2003).
Although aging per se has detrimental effects in the vasculature,
the lack of estrogen due to menopause may add an aggravating
CVD risk factor in women, compared to arterial aging in men.
In middle-aged females, aging-associated vascular dysfunction is
potentiated by lack of estrogen due to menopause or ovariec-
tomy and improves with estrogen replacement (Harman, 2004;
Stice et al., 2009; Novella et al., 2010). Unfortunately, the onset
of menopause coincides with a time when aging-associated dam-
age may be noted, making it particularly difﬁcult to distinguish
between the contributions of aging and the lack of estrogen.
Vascular aging is a natural phenomenon that could be simply
described as a consequence of physical stress, beginning early in
life. Arteries are elastic tissues, susceptible to fatigue, and frac-
ture over time as a consequence of extension-relaxation cycles
during heartbeats (Avolio et al., 1983). In cross-sectional stud-
ies, postmenopausal females taking HRT have less arterial stiffness
than their non-treated peers (Moreau et al., 2003; Sumino et al.,
2005, 2006). Radial artery distensibility ﬂuctuates in accordance
with estrogen levels during menstrual cycles (Giannattasio et al.,
1999). Basic research using animal models of estrogen withdrawal
and aging suggests a modulatory role for estrogen in the mol-
ecular mechanisms to prevent arterial stiffening (Zhang et al.,
2000). A recent study reported that HRT improves arterial com-
pliance, an effect related in part to estrogen actions in the control
of endothelial-dependent vasodilatory tone (Moreau et al., 2012).
Collagen and elastin content of arterial walls is a key factor in
arterial thickening and stiffening. It is mostly regulated by matrix
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metalloproteinases (MMP), enzymes capable of degrading com-
ponents of the extracellular matrix. During aging, MMP activity
decreasesmarkedly, collagen accumulates, and stiffening increases.
Estrogen replacement in ovariectomized rats increasesMMPactiv-
ity and restores aged arteries to structural properties similar to
those of younger animals studied (Zhang et al., 2000).
Aging is also associated with biochemical changes implicated in
CVDdevelopment andprogression.Dysfunctionof both endothe-
lial and smooth muscle molecular signaling appears during the
aging process and favors vasospasm, thrombosis, inﬂammation,
and abnormal cell migration and proliferation (Lakatta and Levy,
2003; Briones et al., 2005; Barton, 2010; Herrera et al., 2010).
Endothelial dysfunction in the elderly has been associated with
malfunctioning of vascular tissue, resulting in atherosclerosis,
hypertension, and coronary artery disease (Lakatta and Levy, 2003;
Herrera et al., 2010), renal dysfunction (Schmidt et al., 2001; Erdely
et al., 2003), and Alzheimer disease (Price et al., 2004). In women,
a slight age-related decrease in endothelium-dependent relaxation
persists until middle age (around 50 years). After that, the declin-
ing response to the endothelium-dependent vasodilator hastens,
even exceeding the rate experienced by men (Taddei et al., 1996).
The mechanisms for age-associated endothelial dysfunction
are multiple, although most are associated with decreased NO
bioavailability (Hayashi et al., 2008; Santhanamet al., 2008; Erusal-
imsky, 2009; Kim et al., 2009). Reduced endothelium-dependent
and NO-mediated vasodilation has been described in both human
and animal models of aging (Kim et al., 2009; Virdis et al., 2010).
Lower NO production in the elderly may be based on decreased
NO synthesis or increased NO degradation. Suggested mecha-
nisms to explain reduced NO production include: (1) decreased
expression of eNOS (Briones et al., 2005; Yoon et al., 2010); (2) a
lack of NO precursor (l-arginine; Santhanam et al., 2008) and
eNOS cofactor tetrahydrobiopterin (BH4; Yoshida et al., 2000;
Eskurza et al., 2005; Meyer et al., 2011); and (3) increased endoge-
nous eNOS inhibitor ADMA (Xiong et al., 2001; Kielstein et al.,
2003). On the other hand, strong evidences support the hypothe-
sis that age-associated increase in oxidative stress and consequent
productionof O−2 is a potent contributor to lowerNObioavailabil-
ity and increased endothelial dysfunction (Jacobson et al., 2007;
Rodriguez-Manas et al., 2009). There is little information to corre-
late the progression of aging with the production/degradation of
NO in women. Although several studies have described decreased
expression of eNOS in senile female rats and mice (Wynne et al.,
2004; Novensa et al., 2011), aging-associated effects on eNOS in
women can be easily confounded with the effects of lack of estro-
gen, since most of these studies grouped women into just two
time-points: premenopausal and menopausal groups.
Even though the decline inNObioavailability could sufﬁciently
explain most of the changes in the functioning of vascular cells,
other molecules crucial to control of vascular function are also
modiﬁed by aging. In the regulation of vascular tone,COX-derived
factors are particularly important as they can induce both vascular
relaxation (PGI2) and contraction (TXA2 and PGH2). Some stud-
ies have reported a prevalence in the production of relaxing COX
factors in the vasculature of young and healthy individuals (Tang
and Vanhoutte, 2008). With aging, COX-dependent vasoconstric-
tors production becomes evident, leading to increased vascular
contraction (Taddei et al., 1997; Rodriguez-Manas et al., 2009).
However, the COX isoform involved in the generation of contrac-
tile prostanoids remains unclear. In functional studies developed
in femoral arteries of aged rats, oxygen free radicals participate
in the augmented endothelium-dependent contractions mediated
by COX-derived prostanoids. Both the constitutive and inducible
isoforms of COX contribute to this endothelial dysfunction (Shi
et al., 2008). Molecular studies performed in endothelial cells from
aged rats showed an increase in mRNA levels of COX-1, COX-
2, and other enzymes involved in the synthesis of prostanoids
(Tang andVanhoutte, 2008), demonstrating the importance of the
arachidonic acid–COXcascade in the endothelial and vascular dys-
function associated with aging. Moreover, functional studies have
demonstrated an interaction between NO and prostanoids path-
ways. In aorta from aged female mice,NO bioavailability increases
when the COX pathway is inhibited; both gene and protein expres-
sion of COX-1 are increased (Novella et al., 2011). Furthermore,
activation of inﬂammatory pathways in the vascular wall plays a
central role in the process of vascular aging.
Even in the absence of traditional risk factors for atherosclero-
sis, an age-associated shift to a proinﬂammatory gene expression
proﬁle, known as endothelial activation, induces upregulation
of cellular adhesion molecules and cytokines, which increases
endothelial–leukocyte interactions and permeability, mechanisms
considered crucial to initial steps in the development of athero-
sclerosis (Herrera et al., 2010; Seals et al., 2011). Accordingly, a
sex-associated difference in inﬂammatory responses during aging
has been proposed. Inﬂammatory atherosclerosis and associated
acute coronary heart disease develop earlier in life in men than in
women (Roger et al., 2011) and are associated with earlier death,
although men and women present the same overall plaque bur-
den (Frink, 2009). In animal models of atherosclerosis, male sex
contributes to a faster and more severe progression of lipid depo-
sition, remodeling, and aortic lesions (Pereira et al., 2010; Surra
et al., 2010).
COULD ESTROGEN DECREASE VASCULAR AGING IN
WOMEN?
With the wide-ranging data from experimental research, estro-
gens might appear to promise protection against the progression
of vascular aging and CVD in women. Epidemiological observa-
tional studies also suggest that postmenopausal women on HRT
are less likely to develop CVD than non-users at the same age
(Grodstein et al., 2000, 2001) Nevertheless, these studies contrast
with the large prospective clinical trials, HERS and WHI, which
failed to show reduced cardiovascular events in postmenopausal
women on HRT. In fact, WHI suggested that HRT was associated
with increased risk to the cardiovascular system (Rossouw et al.,
2002). Possible reasons for this discrepancy have been extensively
discussed and include the average age of women entering most
HRT clinical trials, 65 years and older, which results in a study
population with some degree of aging-associated vascular dam-
age. In addition, participants had been estrogen-deﬁcient for an
average of 10 years before starting HRT, a relatively late start that
could modify the status of ERs and molecular signaling so as to
attenuate the beneﬁts of estrogen. For instance, during aging ERs
can undergo posttranslational modiﬁcations such as methylation,
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which decreases their expression and activity.We recently reported
that aging contributes to increased DNA methylation in female
mice aorta, which could be associated with the decrease in the
modulatory effects of estrogen (Novensa et al., 2011).A few clinical
studies also provide evidence for aging-associated dysregulation
of ER methylation and suggest that focal epigenetic changes in ER
could contribute to decreased estrogen activity and to the devel-
opment of atherosclerosis in elderly women (Post et al., 1999; Kim
et al., 2007).
Detailed examination of WHI data reveals that early initia-
tion of estrogen replacement produces more favorable results than
the later average initiation employed in the WHI studies over-
all (Grodstein et al., 2006; Rossouw et al., 2007; Prentice et al.,
2009). These ﬁndings, togetherwith observational studies,have led
scientists to create the so-called“timing hypothesis” that estrogen-
mediated beneﬁts to prevent CVD only occur when treatment is
initiated before the detrimental effects of aging are established
on vascular walls (Harman, 2006). These effects include endothe-
lial dysfunction and pathophysiological actions, such as increased
vascular calciﬁcation and generalized stiffening of the arterial tree
that increase the prevalence of hypertension and atherosclerosis
(Lakatta and Levy, 2003; Erusalimsky, 2009; Kovacic et al., 2011).
Little information is available on whether and how vascular
effects of estrogen are modiﬁed with aging in females. Aging has
been associated with signiﬁcant reductions in the direct estrogen-
mediated mechanisms of vascular relaxation (Wynne et al., 2004;
LeBlanc et al., 2009; Lekontseva et al., 2010) and inﬂammation
(Pechenino et al., 2011). The lack of estrogen responses in these
animal studies was not related to age-associated changes in the
plasma levels of estrogen or activity of ER, but rather to possi-
ble age-related changes in estrogen-mediated signaling pathways
in the vasculature. Modiﬁcations in the ratio between ERα and
ERβ in older female mice are associated with the lack of pro-
tective effects of estrogen on NO production and with a reversal
in its antioxidant effect to a pro-oxidant proﬁle (Novensa et al.,
2011). Moreover, clinical studies have revealed that CVD risk fac-
tors in postmenopausal women were lower among women aged
50–59 years atHRT initiation (Manson et al., 2007; Sherwood et al.,
2007). These studies clearly establish the complexity of estrogen
effects, which may be inﬂuenced by pathophysiological conditions
including aging and subclinical CVD. Despite convincing argu-
ments by the followers of the “timing hypothesis” the potential
extrapolation of the protective effects of estrogen replacement,
well described in young females, to older women remains con-
troversial. The ﬁeld still lacks detailed experimental and clinical
research on the long-term effects of estrogen and how itmodulates
cardiovascular function during aging.
CONCLUSION AND FUTURE DIRECTION
Our society is aging progressively, and increased life expectancy
enhances the risks for diseases associated with the natural fatigue
of the body, including CVD. Despite this undeniable reality, there
is evidence that vascular aging in women does not follow the same
chronology as in men. The vascular protective effects exerted by
estrogens have been proposed as the major reason for reduced
signs of vascular aging and CVD risk in premenopausal women,
compared to men. When natural estrogen withdrawal occurs and
a woman enters her climacteric stage, effects of sudden vascu-
lar aging become evident, leading to vascular dysfunction and
increased risk of a cardiovascular event. The lack of crucial infor-
mation from clinical trials and the discrepancies in the available
data on the regulation of the female cardiovascular system can
lead to inappropriate diagnosis and treatment of CVD in older
women. Women have been treated like men, despite the notable
sex-associated differences in the elements of aging and disease
processes. Much research effort is still needed to understand age-
and sex-related differences in cardiovascular control, establish the
impact of the menstrual cycle and HRT on vascular function, and
propose new therapeutic strategies to improve CVD diagnosis and
treatment and the overall management of vascular senescence in
women.
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